Autopsy report · NCT04209725

A Study of CPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

“Closed due to slow enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 11 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

SCRI Development Innovations, LLC

Sponsor type

University, hospital or other

Conditions

Leukemia, Myeloid, Acute

Interventions

CPX-351; Quizartinib

Participants

1

Sites

5

Countries

United States

Trials that died the same way

• Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant
  “Study closed due to slow enrollment.” (86% match in meaning)
• Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
  “closed to enrollment due to slow patient accrual” (83% match in meaning)
• Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma
  “Closed short of the enrollment goal, due to slow enrollment and adequate data to address endpoints” (80% match in meaning)
• Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
  “Closed early due to low enrollment rates” (80% match in meaning)
• Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer
  “The study was closed to enrollment due to slow accrual.” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.